Skip to content

Regenxbio RGNX Free cash flow

Free cash flow at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$848.3M+4.0%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$204.76M+67.3%
Biogen logo
BiogenBIIB
$594.3M+167%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
-$81.55M-52.7%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$198M-18.6%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN

Other financials

Income statement

See full
Revenue$6.4M-92.8%
Gross profit$14.9M+35.7%
Operating income-$83.4M-787%
Net income-$90.1M-1,580%
EPS (diluted)-$1.72-1,533%

Balance sheet

See full
Cash & equivalents$15.2M-88.3%
Total debt$71.1M-11.0%
Total equity$21.1M-92.3%
Total assets$341.9M-30.4%

Cash flow

See full
Operating cash flow-$76.2M-327%
CapEx$1.2M+20.6%

Valuation

See full
Market cap$529.38M+24.6%
Enterprise value$585.22M+56.3%
P/S+3.3×

Profitability

See full
Gross margin59.7%+1.0pp
Operating margin-292.3%-613pp
Net margin-330.2%-588pp
FCF margin-269.2%-364pp

Returns & leverage

See full
Return on equity-196.4%-288pp
Debt / equity3.4×+3.1×
Current ratio2.6×-0.3×

Where this comes from

Calculated from Regenxbio’s reported figures.

The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Regenxbio's free cash flow?
Regenxbio (RGNX) reported free cash flow of -$77.42M in Q1 2026.
How has Regenxbio's free cash flow changed year-over-year?
Regenxbio's free cash flow decreased by 337.5% year-over-year, from $32.61M to -$77.42M.
What is the long-term trend for Regenxbio's free cash flow?
Over 4 years (2021 to 2025), Regenxbio's free cash flow has grown at a -1.6% compound annual growth rate (CAGR), from $134.7M to -$126.38M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.